

Cerebral salt wasting in a patient with myeloproliferative neoplasm

Lea Orlik

Kantonsspital Graubunden

Reto Venzin

Kantonsspital Graubunden

Thomas Fehr

Kantonsspital Graubunden

Karin Hohloch (✉ Karin.hohloch@med.uni-goettingen.de)

Georg-August-Universität Göttingen <https://orcid.org/0000-0003-1412-3274>

Case report

Keywords: Cerebral salt wasting syndrome, hyponatremia, myeloproliferative syndrome

Posted Date: May 8th, 2019

DOI: <https://doi.org/10.21203/rs.2.113/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on July 18th, 2019. See the published version at <https://doi.org/10.1186/s12883-019-1393-4>.

Abstract

Background Cerebral salt wasting (CSW) is a rare metabolic disorder with severe hyponatremia and volume depletion usually caused by brain injury like trauma, cerebral lesion, tumor or a cerebral hematoma. The renal function is normal with excretion of very high amounts of sodium in the urine. Diagnosis is made by excluding other reasons for hyponatremia, mainly the syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Background

Cerebral salt wasting (CSW), first described in 1950 [1], is a rare metabolic disorder defined by hyponatremia and extracellular volume depletion in patients with normal adrenal and thyroid function. CSW often occurs after a cerebral injury or trauma, frequently subarachnoidal hemorrhage, brain surgery or stroke. CSW is also reported in patients with carcinomatous or infectious meningitis, encephalitis, poliomyelitis and central nervous tumors. The supposed pathomechanism in CSW is the release of brain natriuretic peptide (BNP) by the injured brain followed by natriuresis and volume depletion [2]. Alternatively, an alteration of sympathetic renal afferent fibers with an increased production of natriuretic peptides has been proposed as an underlying cause for CWS. Therefore, this syndrome was recently also described as renal salt wasting syndrome (RSW)[3]. The existence and prevalence of CSW/RSW is often debated, and the accuracy of discrimination between the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and CSW/RWS is difficult and only possible by determination of the volume status of the patient. The challenge to assess the exact volume status as the sole clinical criteria to distinguish CSW/RSW and SIADH in clinical practice is the major reason for these difficulties. All other clinical and laboratory findings are overlapping in both syndromes [4, 5]. Therefore existence of RWS/CWS is often put in question mostly due to a lack of defined diagnostic criteria and an uncertainty of the pathophysiological mechanisms. Also more recent publications suggest the syndrome should be named "renal salt wasting" rather than "cerebral salt wasting" with several cases described in the literature in patients without cerebral disease [3]. The clinical course with large saline and volume requirement along with simultaneous renal salt loss confirms the diagnosis. Accuracy of diagnosis is crucial due to strikingly different treatment options in SIADH and CSW/RSW. In SIADH fluid restriction is the standard of care, whereas in CSW/RSW saline infusion is the treatment of choice.

Case Report

This is a case report of a 60-year-old male patient, with knee replacement two weeks ago, presented with pain in the upper abdomen and large hematoma around his operated knee. He reported impaired vision in the last two weeks and appeared confused. Clinical examination revealed only slight pain of the upper abdomen. Laboratory results showed severe thrombocytosis (1385 G/l), leukocytosis (49.7 G/l), anemia (98 g/l) and hypoosmolar hyponatremia (105 mmol/l). No clinical or laboratory signs of infection were found. CT scan of thorax and abdomen was inconspicuous. Head MRI showed only a mild

microangiopathy with no evidence of hemorrhage or ischemia nor of sinus venous thrombosis. However, a jugular vein thrombosis was detected.

Because of excessively high platelet and leukocyte counts and thrombosis, a myeloproliferative neoplasm (MPN) was suspected. Bone marrow biopsy (smear and core biopsy) confirmed the diagnosis (figure 1). JAK-2V617F, bcr-abl, CALR- and MPL- mutations turned out negative. PFA 100® test was normal, but von Willebrand factor (vWF) activity and vWF ratio were decreased, consistent with an acquired von Willebrand syndrome (vWS). Based on these results a cytoreductive treatment with hydroxycarbamide was initiated.

Because of the life-threatening degree of hyponatremia the patient was transferred to the ICU. In search of the reason for the hyponatremia, a diagnostic work up was started. After exclusion of renal failure (creatinine 33 $\mu\text{mol/l}$, GFR 133 ml/min), use of diuretics, hypocortisolism and hypothyroidism, SIADH and CSW were the main differential diagnoses. Very low serum sodium (105 mmol/l) and high urinary sodium (22, later increasing up to 240 mmol/l) were consistent with both SIADH and CSW (table 1). However, central venous pressure was low (3 mmHg) and remained low even under high saline infusion indicating persistent hypovolemia, which favored the diagnosis of CSW. Serum sodium was slowly increased with NaCl solution, initially 3% and later 0.9%. After stopping intravenous sodium, sodium level could only be maintained with supplementation of NaCl capsules and fludrocortison 0.1 mg daily, indicating ongoing salt loss. Concomitantly, the patient showed an impressive salt craving. After 3 weeks under continuous hydroxycarbamide therapy, thrombocyte counts normalized, serum sodium returned to normal and all salt substitutions could be stopped (figure 2). In parallel, the impaired mental condition of the patient slowly improved and finally returned to normal. The cytoreductive therapy (hydroxycarbamide 500mg/day) was maintained.

Discussion

Many complications occur in MPN, especially with very high thrombocyte counts. Due to disturbances in microcirculation, patients complain about erythromelalgia (painful redness, swelling and burning) in fingers and toes, impaired vision, dizziness and headache. Most threatening are venous or arterial thromboembolic complications as well as hemorrhages due to impaired thrombocyte function or acquired vWS. Our patient presented with almost all of these symptoms; even the abdominal pain may be interpreted due to microcirculatory disturbances. Exact classification of the MPN could not be worked out, therefore the disorder must be classified as myeloproliferative neoplasm unclassifiable (MPN-U) [6]. Other causes of myeloproliferation (chronic myelogenous leukemia, severe infection, iron deficiency) could be ruled out.

Severe hyponatremia was interpreted as a consequence of CSW/RWS, supported by high urinary sodium loss, persistent sodium loss despite low volume status and clinically exquisite salt craving [7-9]. Differentiation between CSW/RWS and SIADH is challenging, since laboratory findings may be completely overlapping - only volume status (central venous pressure, orthostatic hypotension) is helpful

to distinguish between the two entities (Table 1): whereas SIADH patients suffer from volume expansion due to ADH-mediated renal water retention, CSW/RWS patients have renal sodium loss due to elevated atrial or brain natriuretic peptide. Correct diagnosis is important, since SIADH is treated by fluid restriction, whereas CSW/RWS requires sodium and fluid replacement.

The pathomechanism for CSW/RWS in our patient is speculative: ischemic microtraumata in the brain caused by microcirculatory disturbance and consecutive hypoxia may have promoted CSW/RWS in the context of a preexisting microangiopathy which was seen in the initial MRI scan of the brain. This hypothesis is supported by the prompt and complete recovery of serum sodium and mental disturbances after thrombocytes started to fall under cytoreductive therapy and finally returned into normal ranges. We cannot fully rule out a microangiopathic disorder also in the renal vessels leading to hypoxemia in the kidney as additional pathomechanism for the renal salt wasting. However, the absence of signs of acute renal failure and the concomitant neuropsychiatric symptoms clearly support a primary microangiopathic disorders in the brain. To the best of our knowledge this is the first case describing CSW/RWS as a consequence of MPN.

Declarations

Ethics approval and consent to participate Consent for publication Availability of data and material: NA

Competing interests: The Authors declare no conflict of interest

Funding: NA

Authors' contributions:

All authors have read and approved the manuscript

Lea Orlik& Karin Hohloch: writing the manuscript

Karin Hohloch: Pictures, figures and tables

Reto Venzin& Thomas Fehr: Writing the manuscript

Acknowledgements: NA

Abbreviations

CWS: Cerebral salt wasting,

RWS: Renal salt wasting

MPN: Myeloproliferative Neoplasia,

SIADH: syndrome of inappropriate antidiuretic hormone secretion

References

1. Peters JP, Welt LG, Sims EA, Orloff J, Needham J: A salt-wasting syndrome associated with cerebral disease. *Trans Assoc Am Physicians* 1950, 63:57-64.
2. Lu DC, Binder DK, Chien B, Maisel A, Manley GT: Cerebral salt wasting and elevated brain natriuretic peptide levels after traumatic brain injury: 2 case reports. *Surg Neurol* 2008, 69(3):226-229.
3. Della Corte V, Tuttolomondo A, Pecoraro R, Pinto A: Chronic hyponatremia in a patient with renal salt wasting and without cerebral disease: relationship between RSW, risk of fractures and cognitive impairment. *Intern Emerg Med* 2018, 13(8):1167-1171.
4. Maesaka JK: An expanded view of SIADH, hyponatremia and hypouricemia. *Clin Nephrol* 1996, 46(2):79-83.
5. Maesaka JK, Gupta S, Fishbane S: Cerebral salt-wasting syndrome: does it exist? *Nephron* 1999, 82(2):100-109.
6. Spivak JL: Myeloproliferative Neoplasms. *N Engl J Med* 2017, 377(9):895-896.
7. Palmer BF: Hyponatremia in patients with central nervous system disease: SIADH versus CSW. *Trends Endocrinol Metab* 2003, 14(4):182-187.
8. Palmer BF, Gates JR, Lader M: Causes and management of hyponatremia. *Ann Pharmacother* 2003, 37(11):1694-1702.
9. Singh S, Bohn D, Carlotti AP, Cusimano M, Rutka JT, Halperin ML: Cerebral salt wasting: truths, fallacies, theories, and challenges. *Crit Care Med* 2002, 30(11):2575-2579.

Table 1

Due to technical limitations, Table 1 is only available as a download in the supplemental files section.

Figures




Figure 1

Hypercellular bone marrow at initial diagnosis, Clusters of megakaryocytes (small picture) Legend: * Values up to 240 mmol/l despite hypovolemia were measured in the course of disease.




Figure 2

Time course of platelets and serum sodium.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [supplement1.pdf](#)
- [supplement2.pdf](#)